Corbus Pharmaceuticals Hldgs Inc (CRBP) Stock Price, Quote & News

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 963 0100

Fax: 617 663 6085

Website: www.corbuspharma.com

Address:

500 River Ridge Drive, Norwood, United States

Diefreeandsell Dec. 14 at 1:47 AM

$CRBP Anyone tell me why I should be a buyer here? Upcoming catalysts, Bull Bear case? A bit early in dev pipeline for me but it looks like a good swing trade but not sure if it's bottomed yet, but is close. 👀 Thanks.

0 · Reply

WienersOut4RCAT Dec. 12 at 8:23 PM

$TLRY $GEO $CRBP $SRPT

2 · Reply

WienersOut4RCAT Dec. 12 at 8:22 PM

$TLRY $GEO $CRBP $SRPT

0 · Reply

WienersOut4RCAT Dec. 12 at 8:22 PM

$TLRY $GEO $CRBP $SRPT

0 · Reply

birdmine Dec. 12 at 5:01 PM

$CRBP volume is looking good. Now all we need is some forward momentum.

0 · Reply

shlomiko Dec. 12 at 3:05 PM

$CRBP Typical biotech reaction: sell the news, shake out weak hands. Volume-backed reclaim today suggests accumulation, not deterioration.

0 · Reply

pimisala Dec. 12 at 10:24 AM

$CRBP why down after good news ? ??

2 · Reply

birdmine Dec. 12 at 9:16 AM

$CRBP https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2508603:0-crbp-crb-913-achieved-early-significant-weight-loss-with-minimal-adverse-events-in-phase-i-obesity-study/ Decent news and it’s still dropping!!😑😑😑

1 · Reply

BearTamerTrading Dec. 12 at 1:39 AM

📈 Market Alerts — Bear Tamer Trading (Part 2) 🔥 $RETO — Green-energy / China-related momentum after recent filings and volume expansion. 🔥 $CCCX — SPAC momentum as traders rotated into low-float de-SPAC names. 🔥 $PETS — Oversold bounce play following extended downside and value rotation. 🔥 $BTTC — Crypto mining sympathy move reacting to Bitcoin price action. 🔥 $CRBP — Biotech volatility tied to prior pipeline developments and speculation. Another strong batch of tradable Market Alerts with real catalysts behind the moves 💪 All alerts and management can be verified across our three live streams from today, start to finish. 👉 https://youtube.com/@beartamertrading?si=aPcVk4rTGDlCkAOH

2 · Reply

LuigiDurante Dec. 11 at 11:45 PM

$CRBP the more they read it the lower the stock goes

0 · Reply

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript

Dec 11, 2025, 7:00 AM EST - 2 days ago

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Dec 10, 2025, 4:01 PM EST - 3 days ago

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Nov 6, 2025, 8:00 AM EST - 5 weeks ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 5, 2025, 11:42 AM EST - 5 weeks ago

Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Oct 31, 2025, 2:40 AM EDT - 6 weeks ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Oct 30, 2025, 4:31 PM EDT - 6 weeks ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Oct 20, 2025, 5:05 PM EDT - 7 weeks ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Oct 18, 2025, 3:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Sep 16, 2025, 8:00 AM EDT - 3 months ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Aug 5, 2025, 5:41 PM EDT - 4 months ago

Corbus (CRBP) Q2 Loss Beats Estimates

Jun 25, 2025, 8:00 AM EDT - 6 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 24, 2025, 4:05 PM EDT - 6 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 17, 2025, 3:42 PM EDT - 6 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

May 22, 2025, 8:00 AM EDT - 7 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 7 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Mar 28, 2025, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Feb 14, 2025, 7:30 AM EST - 10 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 11, 2025, 7:30 AM EST - 10 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Jan 28, 2025, 8:00 AM EST - 11 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 6, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

Dec 3, 2024, 7:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 11, 2024, 4:12 AM EST - 1 year ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 2 years ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:13 AM EST - 2 years ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 29, 2024, 2:17 PM EST - 2 years ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 7:18 AM EST - 2 years ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 26, 2024, 7:30 AM EST - 2 years ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Diefreeandsell Dec. 14 at 1:47 AM

0 · Reply

WienersOut4RCAT Dec. 12 at 8:23 PM

$TLRY $GEO $CRBP $SRPT

2 · Reply

WienersOut4RCAT Dec. 12 at 8:22 PM

$TLRY $GEO $CRBP $SRPT

0 · Reply

WienersOut4RCAT Dec. 12 at 8:22 PM

$TLRY $GEO $CRBP $SRPT

0 · Reply

birdmine Dec. 12 at 5:01 PM

$CRBP volume is looking good. Now all we need is some forward momentum.

0 · Reply

shlomiko Dec. 12 at 3:05 PM

$CRBP Typical biotech reaction: sell the news, shake out weak hands. Volume-backed reclaim today suggests accumulation, not deterioration.

0 · Reply

pimisala Dec. 12 at 10:24 AM

$CRBP why down after good news ? ??

2 · Reply

birdmine Dec. 12 at 9:16 AM

1 · Reply

BearTamerTrading Dec. 12 at 1:39 AM

2 · Reply

LuigiDurante Dec. 11 at 11:45 PM

$CRBP the more they read it the lower the stock goes

0 · Reply

Parnell8 Dec. 11 at 10:23 PM

$CRBP trading below cash now

1 · Reply

outlawinvestor1 Dec. 11 at 9:52 PM

$CRBP tried to warn you.

1 · Reply

outlawinvestor1 Dec. 11 at 9:51 PM

$CRBP not surprised.

0 · Reply

Moooonopoly Dec. 11 at 8:41 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $KITT $UUUU $CRML $EOSE $CRBP Soon.

1 · Reply

birdmine Dec. 11 at 8:23 PM

$CRBP let’s see what the post do today. Ridiculous!!

0 · Reply

AStrokeOfLuck Dec. 11 at 8:04 PM

$CRBP

1 · Reply

Zeyker Dec. 11 at 7:41 PM

$GEMI , #IRBT, $CRBP, $NXDR, You can check today's stock picks and Multi AI agent analysis for the market https://www.youtube.com/watch?v=0T5PuyQuL7A

0 · Reply

Cricket23 Dec. 11 at 7:16 PM

$CRBP Very nice data coming from the study done by CRBP. main highlight is this "CRB-913 was safe and well-tolerated across all doses studied." The market is playing games with this stock today, when investors read the study and see the results, money will flow in and CRBP stock price will push higher. We should be seeing $15 soon. Just got to let it run its course. Holding Strong!

0 · Reply

Donniechen12345 Dec. 11 at 7:03 PM

$CRBP AXIL !$$$$$$$ partnership with WALmART 3,000 stores!!!!!!! lers go !!!!!!!AXIL $20 bux :)))) bettter load it !!!

0 · Reply

Etrading Dec. 11 at 6:18 PM

$MIGI PUMP OVER 121 % AFTER MY ALERT !! $5 was buy Watch $IPW $LGHL $CRBP load before pump load this cheap-- i will share this again once they pump too your welcome $SPY

0 · Reply

PulseTraderZ Dec. 11 at 5:54 PM

$CRBP inflammatory and fibrotic disease biotech, derisked assets or partnerships could finally attract larger funds

0 · Reply

birdmine Dec. 11 at 5:28 PM

$CRBP I don’t know why this company is keeping their stock price so low, but they are screwing a lot of people around!!

0 · Reply

Market Cap	170.26M
Revenue (ttm)	0.00
Net Income (ttm)	-40.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	497,700
Avg Vol	524,732
Day's Range	N/A - N/A
Shares Out	17.55M
Stochastic %K	12%
Beta	2.71
Analysts	Strong Sell
Price Target	$42.33